Third Rock shrinks an­oth­er biotech as Cedil­la re­struc­tures, CEO and CBO de­part

Biotech in­cu­ba­tor and in­vestor Third Rock Ven­tures has pruned an­oth­er one of its off­shoots by re­plac­ing the CEO, re­struc­tur­ing and look­ing for part­ners for lead as­sets.

Cedil­la Ther­a­peu­tics, launched in 2018 with $56 mil­lion from the VC firm, is “en­gaged in sev­er­al strate­gic dis­cus­sions re­lat­ed to its lead pro­grams,” a Third Rock spokesper­son told End­points News via email. Part­ner Neil Ex­ter, a 16-year vet­er­an of the in­vest­ment shop, has re­placed Alexan­dra Glucks­mann as CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA